Genomic Vision: Availability of preparatory documents and procedures for participation and voting at the extraordinary general meeting of shareholders of May 23, 2022

BAGNEUX, France, May 02, 2022–(BUSINESSWIRE)–Regulatory News:

Genomic Vision (FR0011799907 – GV, PEA-PME eligible) (Paris:GV)a biotechnology company that develops tools and services dedicated to the analysis and control of genome modifications, announces today the availability of the preparatory documents for its extraordinary general meeting to be held on May 23, 2022 at 2 p.m. company headquarters.

In the current health context, the Company recommends that shareholders give preference to remote voting or by proxy according to the procedures detailed in the notice of the Company’s meeting published in the BALO of April 18, 2022.

For shareholders who would like to attend the general meeting, it is reminded that their welcome is subject to compliance with barrier gestures, and in particular the wearing of a mask for the duration of the meeting.

The preparatory documents are available on request from the Company, or can be consulted on the Company’s website, section Investors / General meetings.

Due to the uncertainties resulting from the current context linked to the Covid-19 epidemic, the Company could be led to modify, subject to the applicable legal and regulatory provisions, the procedures for holding, participating in and voting at the general meeting. . Shareholders are therefore invited to regularly consult the section dedicated to the general meeting.

The Company has also asked the Commercial Court of Nanterre to appoint an ad hoc representative for the purpose of representing shareholders who do not attend the meeting and thereby ensuring that the necessary quorum is met.

***

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company that develops products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in the technologies of editing of the genome and in bioproduction processes. GENOMIC VISION’s proprietary tools based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed for reliable characterization of DNA alterations in the genome. These tools are notably used to monitor DNA replication in cancer cells, for the early detection of cancers and for the diagnosis of genetic diseases. Based in Bagneux, in the Paris region, the company has approximately 30 employees. GENOMIC VISION is listed on the regulated market of Euronext in Paris, Compartment C (Euronext: GV – ISIN: FR0011799907).

www.genomicvision.com

Index Member CAC® Mid & Small and CAC® All-Tradable

WARNING

This press release contains implicitly or expressly forward-looking statements relating to Genomic Vision and its activities. Genomic Vision believes that these forward-looking statements are based on reasonable assumptions. However, no guarantee can be given as to the achievement of the forecasts expressed in these forward-looking statements which are subject to risks, including those described in the “Risk Factors” section of the Universal Registration Document filed with the Autorité des Marchés Financiers (AMF) on April 14, 2022 and which is available on the company’s website (www.genomicvision.com) and changes in economic conditions, financial markets and markets in which Genomic Vision is present. The forward-looking statements contained in this press release are also subject to risks unknown to Genomic Vision or that Genomic Vision does not consider material at this date. The realization of all or part of these risks could cause the actual results, financial conditions, performance or achievements of Genomic Vision to differ materially from the results, financial conditions, performances or achievements expressed in these forward-looking statements.

This press release and the information it contains do not constitute, nor shall they be interpreted as an offer or invitation to sell or subscribe, or the solicitation of any order or invitation to buy or subscribe to Genomic Vision shares. in any country. The distribution of this press release in certain countries may constitute a violation of the legal provisions in force. Persons in possession of the press release must therefore inform themselves of any local restrictions and comply with them.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20220502005625/en/

contacts

Genomic Vision
Dominique Remy-Renou
President of the Management Board
Such. : +33 1 49 08 07 51
investors@genomicvision.com

Ulysses Communication
Press relations
Bruno Arabian
Such. : +33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor Relations
& Strategic Communications
Such. : +33 1 44 71 94 94
gv@newcap.eu

We wish to say thanks to the author of this short article for this incredible material

Genomic Vision: Availability of preparatory documents and procedures for participation and voting at the extraordinary general meeting of shareholders of May 23, 2022


Check out our social media accounts and also other related pageshttps://www.ai-magazine.com/related-pages/